Second Announcement
Vth INTERNATIONAL CONFERENCE ON
CANCER-INDUCED BONE DISEASE (CIBD)
Davos, Switzerland, March 20-24, 2005
Swiss-Images Copyright by Davos Tourismus
Table of Contents
Executive Committee
Robert Coleman ( UK ) - Chairman
Herbert Fleisch (Switzerland) - Local Organiser
T.John Martin ( Australia )
Gregory Mundy ( USA )
Etsuro Ogata ( Japan )
Scientific Committee
Bart Barlogie (USA), Richard Bell (Australia), Jean-Jacques Body (Belgium), Oyvind Bruland (Norway), Philippe Clezardin (France), Denis Clohisy (USA), Peter Croucher (UK), Ignac Fogelman (UK), Matthew Gillespie (Australia), Rob Grimer (UK), Freddie Hamdy (UK), Gabriel Hortobagyi (USA), Toshio Matsumoto (Japan), Suresh Mohla (USA), Gabri van der Pluijm (Netherlands), John Shaughnessy (USA), Matthew Smith (USA), Katherine Weilbacher (USA), Toshiyuki Yoneda (Japan).
Aim
This meeting is the fifth in the series of International CIBD Conferences held in 1997, 1999, 2001 and 2003. As in the past, the aim of the meeting is to present and discuss up-to-date basic and clinical science in the rapidly advancing field of skeletal complications of cancer, and put it into context with all aspects of current and developing therapies.
Venue
The conference will be held at the Congress Center in Davos. Davos is located in the mountains of Graubünden and can be reached in a 3 hour train ride or 2 hour drive from Zurich. It is well known for its skiing, both alpine (Parsenn) and cross-country, and other winter sports facilities which should all be excellent at the time of the meeting.
The nearest airport to Davos is the Zurich Airport. Trains are running hourly from the Airport to Davos. Change train at Zurich Main Station and at Landquart. Be sure to leave the train at Davos Platz or Davos Dorf station, according to the indications on your hotel confirmation, but not at any other Davos station. Bus or porter service from some of the hotels might be available. Otherwise, take the local bus to the hotel or a taxi which costs approximately CHF 15 to CHF 20. The local bus service in Davos is free of charge for persons who are staying in one of the hotels in Davos (special guest card).
Train connections (in English Language) available by clicking .
Program
The meeting will start on Sunday afternoon March 20, 2005 at 4.55 p.m., and will end at 12.30 p.m. Thursday, March 24, 2005. Morning sessions will last from 8.30 a.m. to 12.30 p.m. Afternoon sessions are scheduled from 4.30 p.m. to 7.30 p.m.
Click for more detailed program
Format
The meeting will consist of:
Participation
This conference is open to all interested persons.
Call for Abstracts
The abstracts shall be published as a supplement to Cancer Treatment Reviews. Closing date for abstract submission will be November 1, 2004.
The Abstract booklet will be distributed both to the participants and the subscribers of Cancer Treatment Reviews. It will not be possible to include late abstracts in the published abstract booklet. However, late breaking abstracts for poster presentation will be considered if submitted before February 1, 2005.
Click here for Abstract form
Language
English
Registration Fee
The registration fee for regular participants is EUR 400 if paid before January 1, 2005, and EUR 500 after January 1, 2005. For students up to 24 years old, the registration fee shall be waived. For participants up to 28 years old, the registration fee is EUR 200 if paid before January 1, 2005, and EUR 250 after January 1, 2005.
Click here for Registration Form
Travel Grants (sponsored by Novartis Pharma)
Travel grants will be awarded to some of the young academic investigators (students, postdoctoral fellows or junior faculty [e.g. instructors, assistant professors or equivalents] whose posters have been chosen from submitted abstracts for oral presentation.
Confirmed Speakers and Topics
• Greg Mundy (San Antonio, USA) - The bone microenvironment and metastasis
• Gabriel Hortobagyi (Houston, USA) - Targeted therapies for breast cancer
• Alfred Goldberg (Boston, USA) - Proteosome biology and cancer
• Bart Barlogie (Little Rock, USA) - Proteosome inhibitors and multiple myeloma
• John Shaughnessey (Little Rock, USA) - DKK and multiple myeloma. Treatment implications for tumour and bone
• Steven Pals (Amsterdam, Netherlands) - Wnt signalling in myeloma – paracrine and autocrine mechanisms
• Toshio Matsumoto (Tokushima, Japan) - MIP 1a in multiple myeloma – bone implications
• Toshiyuki Yoneda (Osaka, Japan) – Facilitation of myeloma colonization in bone by a4b1 integrin-VCAM-1 interactions
• Peter Croucher (Sheffield, UK) - Non osseous effects of osteoprotegerin
• Christoph Klein (Munich, Germany) – Genetic analysis of systemic breast cancer progression
• Richard Iggo (Lausanne, Switzerland) - Genetic profiling and decision making in cancer treatment
• Leland WK Chung (Atlanta, USA) - Prostate cancer tropism for bone
• Philippe Clezardin (Lyon, France) A novel integrin antagonist – evaluation in bone growth tumour models
• Matthew Gillespie (Melbourne, Australia) - Tumour and bone effects of PTHrP: implications for breast cancer behaviour
• Gabri van der Pluijm (Leiden, Netherlands) – Epithelium-Mesenchyme Transition in Bone Metastasis: New Therapeutic Opportunities
• Brendan Boyce ( Rochester, USA)– Src kinase inhibitors in bone disease
• Richard Bell (Geelong, Australia) - What’s new in breast cancer management?
• George Thalmann (Bern, Switzerland) – Advances in treatment approaches to prostate cancer
• Patrick Mantyh (Minneapolis, USA) - Mechanisms of bone pain
• Mike Rogers (Aberdeen, UK) Do bisphosphonates act on tumour cells as well as bone?
• Rob Coleman (Sheffield, UK) - Developing more rational use of bisphosphonates in malignancy
• Ignac Fogelman (London, UK) - PET scanning in metastatic bone disease
• Alistair Stirling (Birmingham, UK) - Spinal re-constructive surgery
• Henrik Bauer (Stockholm, Sweden) – Surgical treatment for pathological fracture
• Ed Chow (Toronto, Canada) - Pain and structural effects of external beam radiotherapy
• Valerie Lewington (London, U.K.) – Radio-isotope treatments for bone metastases
• Richard Schlenk (Cleveland, USA) - Interventional radiology for spinal metastases
• Matt Smith (Boston, USA) - Androgen deprivation and bone
• Richard Eastell (Sheffield, UK) - Aromatase inhibitors and bone
• Pierre Delmas (Lyon, France) – Role of bone markers in cancer induced bone disease
• Socrates Papapoulos (Leiden, Netherlands) - Lessons from post menopausal osteoporosis for cancer clinicians
Satellite Symposia
Amgen - click for detailed program
Novartis - click for detailed program
Roche - click for detailed program
Hotel Accommodation
Rooms will be available in various hotels, prices ranging between CHF 117 and CHF 253 per person and night for room, breakfast and dinner, service, taxes and VAT included; bed and breakfast only between CHF 95 and CHF 218. Private apartments ( for groups ) available at lower costs.
Click here for hotel booking information
Scientific Exhibition
An international exhibition of scientific and technical equipment will be held.
Conference Dinner
Hotel Steigenberger Belvedere - Wednesday 23rd March
CME Approval
The Conference CME-0231 has been awarded 24 CME credit points by the Accreditation Council of Oncology in Europe (ACOE).
Online Information
www.ibmsonline.org/cancerbone.htm
Secretariat
Heidi Triet
Office Prof. H. Fleisch
Effingerstrasse 40
CH-3008 Berne
Switzerland
Telephone: +41 31 389 92 76
Fax: +41 31 389 92 84
E-mail:
For any further information, please contact the Secretariat.
- Keynote addresses of 45 minutes
- Invited talks of 30 minutes
- Hot topics presentations of 20 minutes
- Oral presentations of 10 minutes chosen from the poster presentations
- Poster sessions
- Industry sponsored symposia